These observations support the view that (i) the expression of ectonucleotidases is linked to the production of ADO in the BM plasmatic fluid of MM patients and (ii) that metabolic reprogramming may allow mPCs to construct a microenvironment that favors their survival and protects them from the host immune system. This evidence concerns the gene ADO and Miyoshi myopathy.